Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas

Podrobná bibliografie
Hlavní autoři:	Ahmad, M, Catto, J, Azzouzi, A, Cross, S, Feeley, K, Eaton, C, Meuth, M, Hamdy, F, Rehman, I
Médium:	Journal article
Jazyk:	English
Vydáno:	2003

Podobné jednotky

Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations
Autor: Rehman, I, a další
Vydáno: (2004)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
Autor: Rehman, I, a další
Vydáno: (2004)

Tissue microarray immunohistochemistry and cluster analysis confirms the validity of candidate proteins in prostate cancer identified by proteomic analysis of urine
Autor: Rehman, I, a další
Vydáno: (2005)

A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder
Autor: Yates, DR, a další
Vydáno: (2006)

Genetic instability and transitional cell carcinoma of the bladder.
Autor: Catto, J, a další
Vydáno: (2004)

Calgizzarin (S100A11) immunostaining pattern is altered in prostate cancer suggesting a role in tumourigenesis
Autor: Rehman, I, a další
Vydáno: (2003)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Autor: Catto, J, a další
Vydáno: (2005)

Promoter hypermethylation identifies progression risk in bladder cancer.
Autor: Yates, DR, a další
Vydáno: (2007)

The use of proteomics in urological research
Autor: Rehman, I, a další
Vydáno: (2005)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
Autor: Yates, DR, a další
Vydáno: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
Autor: Yates, DR, a další
Vydáno: (2005)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
Autor: van Oers, J, a další
Vydáno: (2009)

Clinically localised prostate cancer is microsatellite stable.
Autor: Azzouzi, A, a další
Vydáno: (2007)

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract.
Autor: Catto, J, a další
Vydáno: (2003)

Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation
Autor: Cross, S, a další
Vydáno: (2005)

A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis
Autor: Carolien M. Woolthuis, a další
Vydáno: (2013-10-01)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
Autor: Rehman, I, a další
Vydáno: (2008)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
Autor: Glen, A, a další
Vydáno: (2008)

Phosphorylation-dependent migration of retinoblastoma protein into the nucleolus triggered by binding to nucleophosmin/B23.
Autor: Takemura, M, a další
Vydáno: (2002)

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Autor: Dhawan, D, a další
Vydáno: (2006)

Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids
Autor: Patricia M. Day, a další
Vydáno: (2015-12-01)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
Autor: Catto, J, a další
Vydáno: (2007)

Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder
Autor: Yates, D, a další
Vydáno: (2005)

Urinary Bladder Xanthoma – Is Immunohistochemistry Necessary?
Autor: M. Raghavendran, a další
Vydáno: (2016-09-01)

DNA promoter methylation in urothelial cancer: a feature of the invasive phenotype and a novel therapeutic target
Autor: Catto, J, a další
Vydáno: (2006)

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
Autor: Catto, J, a další
Vydáno: (2003)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
Autor: Evans, C, a další
Vydáno: (2009)

Gli1 appears to be constitutively expressed in the lumenal epithelial cells of the prostate but not in the basal cell layer or the mesenchyme
Autor: Spencer, A, a další
Vydáno: (2004)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
Autor: Catto, J, a další
Vydáno: (2003)

Nucleophosmin 1 expression in acute myeloid leukemia
Autor: Mohammad Davoudi, a další
Vydáno: (2015-10-01)

Nucleophosmin 1 expression in acute myeloid leukemia
Autor: Mohammad Davoudi, a další
Vydáno: (2015-09-01)

Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Autor: Rehman, I, a další
Vydáno: (2005)

Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target
Autor: Catto, J, a další
Vydáno: (2006)

NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization
Autor: Markéta Šašinková, a další
Vydáno: (2021-01-01)

Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma.
Autor: Roupret, M, a další
Vydáno: (2004)

Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation
Autor: Duangmano Suwit, a další
Vydáno: (2012-10-01)

Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma.
Autor: Rouprêt, M, a další
Vydáno: (2005)

Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Autor: Rehman, I, a další
Vydáno: (2004)

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.
Autor: Catto, J, a další
Vydáno: (2010)

Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.
Autor: Grzegorz Sarek, a další
Vydáno: (2010-03-01)